iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

iShares Global Healthcare ETF provides broader diversification with 110 holdings compared to 25 positions in VanEck Biotech ETF VanEck Biotech ETF delivered a 30.8% 1-year total return but has experienced a 39.9% historical maximum drawdown iShares Global Healthcare ETF offers a 1.5% trailing-12-month dividend yield and a longer history since its 2001 launch

The Motley Fool • Jul 23, 2026

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?

iShares Global Healthcare ETF provides lower-cost exposure to the broader medical sector than iShares Biotechnology ETF. iShares Biotechnology ETF has delivered higher 1-year total returns but with significantly greater price volatility.

The Motley Fool • Jul 23, 2026

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

The iShares Global Healthcare ETF (IXJ) charges a lower expense ratio and pays a higher dividend yield than the Simplify Health Care ETF (PINK). PINK has delivered stronger one-year and three-year returns than IXJ.

The Motley Fool • Jul 22, 2026

Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ

The iShares Global Healthcare ETF provides broader exposure with 110 holdings across various sub-sectors compared to the 26 positions in the VanEck Pharmaceutical ETF The VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% and a higher trailing dividend yield of 2.00% While the iShares Global Healthcare ETF has experienced lower historical drawdowns, the VanEck Pharmaceutical ETF has delivered higher total returns over the last five years

The Motley Fool • Jul 23, 2026

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

IXUS offers greater diversification with 110 holdings compared to 60 for RSPH. IXUS provides a significantly higher dividend yield than RSPH.

The Motley Fool • Jul 21, 2026

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio of 0.40% compared to 0.55% for First Trust NYSE Arca Biotechnology Index Fund.

The Motley Fool • Jul 21, 2026

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?

iShares Global Healthcare ETF offers broader diversification with 110 global holdings compared to 29 U.S. stocks for Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has a higher expense ratio of 0.57% but outperformed over the past year with a 44.90% total return iShares Global Healthcare ETF provides a higher trailing-12-month dividend yield of 1.50% while charging a lower expense ratio than its peer

The Motley Fool • Jul 20, 2026

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?

iShares Global Healthcare ETF offers broader exposure with 110 holdings across the global healthcare sector, while VanEck Pharmaceutical ETF concentrates on 26 pharmaceutical-specific companies VanEck Pharmaceutical ETF has delivered higher total returns over the last year and five years alongside a higher dividend yield of 2.0% iShares Global Healthcare ETF manages significantly more assets at $4.1 billion but carries a slightly higher expense ratio of 0.4% compared to 0.36% for the VanEck fund

The Motley Fool • Jul 20, 2026

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?

The Invesco Nasdaq Biotechnology ETF (IBBQ) carries a lower expense ratio than the iShares Global Healthcare ETF (IXJ). IXJ offers broad global exposure across the healthcare sector, while IBBQ is concentrated exclusively in Nasdaq-listed biotechnology and pharmaceutical companies.

The Motley Fool • Jul 18, 2026

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its two largest holdings accounting for over 43.00% of the total portfolio iShares U.S. Pharmaceuticals ETF has outperformed on a one-year and five-year total return basis compared to iShares Global Healthcare ETF

The Motley Fool • Jul 19, 2026